J&J submits PMA for personalized sedation
This article was originally published in The Gray Sheet
Executive Summary
Ethicon Endo-Surgery unit of Johnson & Johnson submits PMA application to FDA for its Sedasys computer-assisted personalized sedation system. The device is intended for use by physician/nurse teams to administer minimal to moderate doses of propofol to sedate patients undergoing colonoscopies for the diagnosis and screening of colorectal cancer, as well as upper gastrointestinal disorders. The PMA is supported by a 1,000-patient, U.S. trial randomizing Sedasys to the current standard of care, which consists of physician-administered benzodiazepine and opioids
You may also be interested in...
DePuy Orthopaedics Counting On Knee Pipeline To Regain Market Lead
Johnson & Johnson/DePuy Orthopaedics expects to regain the lead in the knee repair market with a series of new device launches planned for the next few years, executives said during a day-long meeting with Wall Street analysts June 5
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.